

Suppl. Table 1. Effects of eltrombopag addition at different time points during the HCMV replication cycle using human foreskin fibroblasts infected with HCMV strain Hi91 at an MOI of 0.02.

Time of drug addition	IC₅₀¹ (nM)
Continuous starting from virus infection	415 ± 197
24h pre-treatment	> 10
During the 1h virus adsorption period	8,979 ± 1153
1h post infection	233 ± 35
24h post infection	358 ± 105
48h post infection	2,493 ± 795

¹ Concentration that reduces HCMV late antigen expression by 50%

Suppl. Table 2. Effects of eltrombopag on HCMV late antigen (LA) expression in different cell types infected with different virus strains and isolates as determined 120h post infection. Concentrations that reduce LA expression by 50% (IC₅₀) are provided. The investigated eltrombopag concentrations did not affect cell viability.

Virus strain	Eltrombopag IC₅₀ (nM)	
	HFFs	ASCs
Hi91	415 ± 197	4331 ± 1450
Davis	1182 ± 38	265 ± 77
Towne	4230 ± 257	2303 ± 616
U1	110 ± 7	99 ± 30
U59	3372 ± 1253	296 ± 84
U75	389 ± 93	1828 ± 491